Clinical Efficacy Of Entecavir Combined With Xiaozhang Fang In The Treatment Of Liver Cirrhosis After Hepatitis B

Objective:To observe the clinical efficacy of entecavir combined with Xiaozhang Fang in the treatment of Liver cirrhosis after hepatitis B.Method:Arandomized controlled studycollecting 93 patients of hepatitis B patie-nts with liver cirrhosis that meet the inclusion criteria,was divided into the treatment group(treated with entecavir alone)and the control group(treated with entecavir and the Xiaozhang Fang).They were both observed for 12 months.Compare the changes of TCM syndrome score,liver function,prothrombin time,HBV-DNA quantification,cellular immunity,liver fibrosis index,APRI score,FIB-4 score,Fibro Scan,upper abdominal B-score,liver CT grading,liver fibrosis and liver cancer risk genotype(TNF-αgenotype)before and after the treatment,and evaluate the clinical efficacy of Xiaozhang Fang in treating liver cirrhosis with liver depression and spleen deficiency.Result:1.After treatment,TCM syndrome integral decreased significantly in the treatment group,and there was a significant difference between the treatment group and the control group(P<0.01).The total effective rate was 78.72%in the treatment group and 56.52%in the control group.The clinical efficacy of the treatment group was better than that of the control group,and the difference was statistically significant(P<0.05).2.The level of ALT in the treatment group decreased significantly after treatment,and the curative effect was better than that in the control group.The difference was statistically significant(P<0.01).The level of AST in the treatment group decreased significantly after treatment,and the improvement of AST in the treatment group was better than that in the control group(P<0.05).After treatment,the level of ALB increased slightly in the treatment group,but slightly decreased in the control group,there was no significant difference between the treatment group and the control group(P>0.05).The treatment group TBIL decreased after treatment,compared with before treatment,the difference was significant statistically significant(P<0.01),but compared with the control group,the difference was not statistically significant(P>0.05).3.The level of prothrombin time in the treatment group had a slight decline before and after treatment,and the level of prothrombin time in the control group rose slightly after treatment,and the difference was statistically significant(P<0.05).4.The level of HBV-DNA in the treatment group decreased significantly after treatment,and the difference between the treatment group and the control group was statistically significant(P<0.01).After treatment,the negative rate of HBV-DNA in treatment group was 87.23%,while in control group,the negative rate of HBV-DNA was 76.09%,the clinical efficacy of the treatment group was better than that of the control group,but there was no significant difference between the treatment group and the control group(P>0.05).5.The level of NK cells and CD8~+T increased significantly in the treatment group after treatment,and the curative effect was better than that in the control group(P<0.05).The levels of CD4~+T and CD4~+T/CD8~+T were all lower andtherewereno difference between the treatment group and control group(P>0.05).6.The level of PCIII and LN before and after treatment in treatment group and control group was basically the same.There was no significant difference between the treatment group and the control group(P>0.05).The levels of IV-C and HA in the treatment group were significantly lower than those in the control group after treatment,and the difference was statistically significant(P<0.01).7.The APRI score of the treatment group decreased significantly after treatment.The curative effect of the treatment group was better than that of the control group,and the difference was statistically significant compared with the control group(P<0.05).8.After treatment,the FIB-4 score of the treatment group was significantly lower than that before the treatment(P<0.01),and the effect was better than the control group,but there was no statistical difference compared with the control group(P>0.05).9.After treatment,the Fibro Scan(k Pa value)decreased significantly and the degree of liver cirrhosis improved in the the treatment group.The effect was better than the control group and the difference is extremely significant(P<0.01).10.After treatment,B-ultrasonography and CT grade of liver cirrhosis was improved in the treatment group,there was no significant change in the control group,but there was no significant difference between the treatment group and the control group(P>0.05).11.In the treatment group,45 cases of liver fibrosis and liver cancer risk genotype(TNF-αgenotype)were GG type,2 cases were GA type,and the control group were all GG type.The difference was not statistically significant between the treatment group and the control group(P>0.05).Conclusion:1.Entecavir combined with"Xiaozhang Fang"can obviously relieve the clinical symptoms of hepatitis B cirrhosis patients with liver depression and spleen deficiency.2.Entecavir combined with"Xiaozhang Fang"can promote the recovery of liver function,regulate cellular immunity and inhibit the replication of hepatitis B virus.3.Entecavir combined with"Xiaozhang Fang"can reduce the degree of liver cirrhosis in patients,significantly reduce the liver fibrosis index,Fibro Scan level and the APRIscore.